These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18666366)

  • 21. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries.
    Brassard P; Amiri F; Schiffrin EL
    Hypertension; 2005 Sep; 46(3):598-606. PubMed ID: 16043661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
    Parvanova A; Chiurchiu C; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2005 Sep; 6(11):1931-42. PubMed ID: 16144512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D
    Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saga of renin-angiotensin system and calcium channels in hypertensive diabetics: does it have a therapeutic edge?
    Kumar AH; Ramarao P
    Cardiovasc Drug Rev; 2005; 23(2):99-114. PubMed ID: 16007228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective Ang II (AT1) receptor blockade: a rational approach to end-organ protection in hypertension.
    Burnier M
    Int J Clin Pract Suppl; 2000 Aug; (111):9-13. PubMed ID: 15977401
    [No Abstract]   [Full Text] [Related]  

  • 29. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II receptor blockade and end-organ protection.
    Chung O; Unger T
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):150S-156S. PubMed ID: 10619595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling.
    Zhu YC; Zhu YZ; Lu N; Wang MJ; Wang YX; Yao T
    Clin Exp Pharmacol Physiol; 2003 Dec; 30(12):911-8. PubMed ID: 14678229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin II receptor blockers].
    Verdecchia P; Cavallini C; Angeli F; Andreani F; Garofoli M; Reboldi GP; Ambrosio G
    G Ital Cardiol (Rome); 2007 Aug; 8(8):491-7. PubMed ID: 17695700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide.
    Miura S; Nakayama A; Tomita S; Matsuo Y; Suematsu Y; Saku K
    Clin Exp Hypertens; 2015; 37(5):353-7. PubMed ID: 25496380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do angiotensin II antagonists provide benefits beyond blood pressure reduction?
    de Champlain J
    Adv Ther; 2005; 22(2):117-36. PubMed ID: 16020402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II blockade and renal protection.
    Kobori H; Mori H; Masaki T; Nishiyama A
    Curr Pharm Des; 2013; 19(17):3033-42. PubMed ID: 23176216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.